US equities |
MU $1,087.00 ▲+3.96% NVDA $236.78 ▼-1.03% SNDK $1,722.23 ▲+3.72% SPCX $167.21 ▼-2.74% AMD $645.34 ▼-0.63% INTC $112.65 ▲+0.13% TSLA $377.05 ▼-0.95% AAPL $336.33 ▲+0.81%
FinancialContent

Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

11.90 -0.17 (-1.41%)
Delayed Quote Updated: 2:27 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amarin Corporation plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
– Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action and Utility as A Complementary Therapy for Residual Risk Reduction in Combination with Statins in Important... 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript ↗
AMRN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
1-For-20 Ratio Change Initiated to Increase Per Share Market Price of Amarin’s ADSs in Effort to Maintain Nasdaq Listing 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Earnings Scheduled For March 12, 2025 ↗
 
Via Benzinga
News headline image
Amarin Receives National Reimbursement for VAZKEPA® in Austria
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Receives National Reimbursement for VAZKEPA® in Italy
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Appoints Peter Fishman Chief Financial Officer
Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks You'll Regret Missing In Q4 ↗
 
Via Benzinga
News headline image
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript ↗
AMRN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Announces Two Upcoming Investor Events
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript ↗
AMRN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
News headline image
3 Breakthrough Stocks Under $10 Set for Massive Upside ↗
Discover the top breakthrough stocks under $10 with strong fundamentals and strategic advantages to hit massive upside. 
Via InvestorPlace
News headline image
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
From Amarin Corporation plc
Via GlobeNewswire
News headline image
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
News headline image
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Amarin Board of Directors Announces CEO Transition
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Amarin Corporation plc
Via GlobeNewswire
News headline image
AMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024 ↗
AMRN stock results show that Amarin Corp beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >